BiotechTube
Genclis

Genclis

Strasbourg, France· Est.
genclis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Genclis is a biotechnology company pioneering a novel drug discovery and development platform based on Transcription Infidelity (TI), a biological mechanism that generates immunologically active variant proteins from mRNA. Its pipeline includes programs in veterinary and human allergies, severe COVID-19, Type 1 Diabetes, and Lou Gehrig's disease (ALS), with its veterinary allergy candidate appearing most advanced. The company is privately held, led by co-founder and CEO Bernard Bihain, and operates with a cautious, capital-efficient business model focused on robust preclinical de-risking before clinical advancement.

AllergyInfectious DiseaseAutoimmune DiseaseNeurodegenerative Disease

Technology Platform

Transcription Infidelity (TI) platform that identifies and utilizes novel protein variants created from mRNA with transcription-induced gaps/frameshifts. These TI proteins have unique immunogenic properties and can be used to elicit, enhance, or modulate antibody responses for therapeutic purposes.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The TI platform offers a novel approach to immune modulation with potential applications across a wide range of allergic, autoimmune, and inflammatory diseases.
Success in the advanced veterinary allergy program could provide early validation, revenue potential, and a de-risked path for human therapeutic development.
The high unmet needs in indications like ALS and Type 1 Diabetes represent large market opportunities for a successful therapy.

Risk Factors

The company faces high scientific risk as its core TI technology is novel and unproven in late-stage human trials.
As a small, private, pre-revenue company, it is highly dependent on securing funding to advance its pipeline.
It also faces significant competitive and clinical development risks in its chosen, challenging therapeutic areas.

Competitive Landscape

Genclis competes in crowded and competitive therapeutic areas. In allergies, it faces established pharmaceutical companies and biotechs developing biologics and immunotherapies. In ALS and Type 1 Diabetes, it competes against numerous entities pursuing diverse mechanisms. Its differentiation hinges entirely on the unique efficacy and safety profile of its TI-based therapeutics, which remains to be clinically demonstrated.

More companies in Diagnostics & Precision Medicine →More companies in France →